@article{d67e8f31f6084cf59fefe0d5630db0fd,
title = "Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study",
author = "Gordon, \{Naheema S.\} and Baxter, \{Laura A.\} and Anshita Goel and Roland Arnold and Baljit Kaur and Wenyu Liu and Pirrie, \{Sarah J.\} and Syed Hussain and Richard Viney and Daniel Ford and Anjali Zarkar and Wood, \{Mary A.\} and Timur Mitin and Thompson, \{Reid F.\} and James, \{Nicholas D.\} and Ward, \{Douglas G.\} and Bryan, \{Richard T.\}",
note = "Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee {\textendash} CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: Timur Mitin: UpToDate, Inc (royalties for chapter authorship), Novocure (study grant and advisory board), AstraZeneca (advisory board). Richard T. Bryan: Olympus Medical Systems (advisory board), Janssen (advisory board), UroGen Pharma (research grant), QED Therapeutics (research grant), Nonacus Limited (advisory board). Douglas G. Ward: Nonacus Limited (advisory board). Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee {\textendash} CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. ",
year = "2022",
month = jan,
day = "1",
doi = "10.1111/bju.15589",
language = "English (US)",
volume = "129",
pages = "32--34",
journal = "BJU International",
issn = "1464-4096",
publisher = "John Wiley and Sons Inc.",
number = "1",
}